Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

Leukemia

Volumn 22, Issue 7, 2008, Pages 1446-1449

  Stamatopoulos, K ^a   Papadaki, T ^b   Pontikoglou, C ^c   Athanasiadou, I ^a   Stavroyianni, N ^a   Bux, J ^d   Batsis, I ^a   Pyrovolaki, K ^c   Paterakis, G ^e   Anagnostou, D ^b   Anagnostopoulos, A ^a   Papadaki, H A ^c  

^a Department of Histopathology   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d Blood Service West of the German Red Cross   (Germany)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; LARGE CELL LYMPHOMA; LETTER; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MAINTENANCE THERAPY; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CYTOKINES; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE SUBSETS; LYMPHOMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA;

EID: 47549098821     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405077     Document Type: Letter

References (10)

1. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K et al. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26: 597-600.
2. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003; 102: 1557-1558.
3. Chaiwatanatom K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-918.
4. Cairoli R, Grillo G, Tedeschi A, D'Avanzo G, Marengo P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89 361-363.
5. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E et al. Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47: 1013-1017.
6. Dunleavy K, Hakim F, Kyung Kim H, Janik JE, Grant N, Nakayama T et al B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor and granulocyte homeostasis. Blood 2005; 106: 795-802.
7. Rezvany MR, Jeddi-Tehrani M, Wigzell H, Osterborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 2003; 101: 1063-1070.
8. Liu JH, Wei S, Lamy T, Eppling-Burnette PK, Starkehaum G, Djeu JY et al. Chronic neutropenia mediated by fas-ligand. Blood 2000; 95: 3219-3222.
9. Coakley G, Iqbal M, Brooks D, Panayi GS, Ianchbury JS. CD8CD57 T cells from healthy elderly subjects suppress neutrophil development in vitro: Implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 2000; 43: 834-843.
10. Sokol L, Loughran Jr TP. Large granular lymphocyte leukemia. Oncologist 2006; 11: 263-273.